Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation
- PMID: 1783916
- PMCID: PMC1014678
- DOI: 10.1136/jnnp.54.12.1061
Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation
Abstract
The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical